1-(t-butoxycarbonyl)nipecotoyl chloride | 816455-27-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(t-butoxycarbonyl)nipecotoyl chloride
• 英文别名: N-Boc-piperidine-3-carbonyl chloride；tert-butyl 3-(chlorocarbonyl)piperidine-1-carboxylate；tert-butyl 3-carbonochloridoylpiperidine-1-carboxylate
• CAS: 816455-27-3
• 化学式: C₁₁H₁₈ClNO₃
• 分子量: 247.722
• InChiKey: FVOJMAURFOVTPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(t-butoxycarbonyl)nipecotoyl chloride 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 3-(4-Amino-phenylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Investigation of platelet aggregation inhibitory activity by phenyl amides and esters of piperidinecarboxylic acids

  摘要：

  A series of anilides and phenyl esters of piperidine-3-carboxylic acid (nipecotic acid) were synthesized and tested for the ability to inhibit aggregation of human platelet rich-plasma triggered by adenosine 5'-diphosphate (ADP) and adrenaline. As a rule, amides were about two times more active than the corresponding esters, and derivatives bearing substituents at the para position of the phenyl ring were significantly more active than the meta-substituted ones. Among the tested compounds, 4-hexyloxyanilide of nipecotic acid (18a) was found to be the most active one, its IC50 value being close to that of the most active bis-3-carbamoyl-piperidines reported in literature (ca. 40 muM) and aspirin (ca. 60 muM) in ADP- and adrenaline-induced aggregation, respectively. Compared with the isomeric 4-hexyloxyanilides of piperidine-2-carboxylic (pipecolinic) and piperidine-4-carboxylic (isonipecotic) acids, compound 18a showed higher activity, and a Hansch-type quantitative structure-activity relationship (QSAR) study highlighted lipophilicity and increase in electron density of the phenyl ring as the properties which mainly increase the antiplatelet activity (r(2) = 0.74, q(2) = 0.64). The interaction of nipecotoyl anilides with phosphatidylinositol, a major component of the inner layer of the platelet membranes, was investigated by means of flexible docking calculation methods to give an account of a key event underlying their biological action. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00599-0
• 作为产物：
  描述：

  1-BOC-哌啶-3-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 1-(t-butoxycarbonyl)nipecotoyl chloride
  参考文献：
  名称：

  Carnitine Conjugate of Nipecotic Acid: A New Example of Dual Prodrug

  摘要：

  作为通过营养共轭物改善低效药物进入大脑的一个新实例，我们将左旋肉碱与尼泊金酸共轭，并评估了这种新型实体拮抗 PTZ 引起的惊厥的能力。

  DOI：

  10.3390/molecules14093268

文献信息

• [EN] BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS<br/>[FR] BENZOFUROPYRIMIDINONES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：EXELIXIS INC

  公开号：WO2009086264A1

  公开（公告）日：2009-07-09

  A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

  根据公式I的化合物：或其药用可接受盐；其中R1、R2、R3a、R3b、R3c和R3d如规范中所定义，以及其药物组合物和使用方法。
• [EN] PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSES DE PYRIMIDINE UTILES POUR LE TRAITEMENT DES INFLAMMATIONS
  申请人：PHARMACIA CORP

  公开号：WO2005040133A1

  公开（公告）日：2005-05-06

  Compounds of Formula (I): wherein A, X, R2 and R4 are as defined herein, are disclosed.

  式(I)的化合物：其中A、X、R2和R4如本文所定义，已被披露。
• [EN] INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLE/PYRZOLO[4,3-C]PYRIDINE UTILISÉS COMME INHIBITEURS DE JNK, COMPOSITIONS ET MÉTHODE S'Y RAPPORTANT ET PRODUITE INTERMÉDIAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2004113303A1

  公开（公告）日：2004-12-29

  The present invention relates to new compounds of formula (I) in which:X is CR4 or N; R1 is -OR5, -NHCOR6 or -NR6R7; R2 is hydrogen, Oar1 or -NHAr1 wherein Ar1 is aryl optionally substituted with one or more of R8, -OR8, -NR8R9, -CONR8R9, -COOR8, -NR8COR9, -SR8, -SO2NR8R9, -NR8SO2 R9, halogen, cyano, or nitro; R3 is hydrogen or -NHAr2 wherein Ar2 is benzene optionally substituted with one or more of R8, -OR8, -NR8R9, halogen or nitro, wherein R2 and R3 is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式（I）的新化合物，其中：X为CR4或N；R1为-OR5，-NHCOR6或-NR6R7；R2为氢，Oar1或-NHAr1，其中Ar1是芳基，可选择地取代一个或多个R8，-OR8，-NR8R9，-CONR8R9，-COOR8，-NR8COR9，-SR8，-SO2NR8R9，-NR8SO2R9，卤素，氰基或硝基；R3为氢或-NHAr2，其中Ar2是苯，可选择地取代一个或多个R8，-OR8，-NR8R9，卤素或硝基，其中R2和R3不同时为氢；一种制备它们的方法和在其中使用的新中间体，含有所述治疗活性化合物的制药配方以及所述活性化合物在治疗中的使用。
• Carnitine Conjugate of Nipecotic Acid: A New Example of Dual Prodrug
  作者：Carmela Napolitano、Martina Scaglianti、Emanuela Scalambra、Stefano Manfredini、Luca Ferraro、Sarah Beggiato、Silvia Vertuani

  DOI：10.3390/molecules14093268

  日期：——

  As a novel example of improved entry of poorly delivered drugs into the brain by means of nutrient conjugates, L-carnitine was conjugated to nipecotic acid and the capacity to antagonize PTZ-induced convulsions of this novel entity was evaluated.

  作为通过营养共轭物改善低效药物进入大脑的一个新实例，我们将左旋肉碱与尼泊金酸共轭，并评估了这种新型实体拮抗 PTZ 引起的惊厥的能力。
• Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
  申请人：Fleck Roman Wolfgang

  公开号：US20090227588A1

  公开（公告）日：2009-09-10

  Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.

  本发明涉及对可溶性环氧水解酶（sEH）活性的化合物，其组成物和使用和制备它们的方法。